公开(公告)号：US20240156962A1

公开(公告)日：2024-05-16

申请号：US18499720

申请日：2023-11-01

申请人： LEGEND BIOTECH USA INC. ,  JANSSEN BIOTECH, INC.

发明人： Lida PACAUD ,  Muhammad AKRAM ,  Dong GENG ,  Jordan SCHECTER ,  Carolyn Chang JACKSON ,  Enrique ZUDAIRE UBANI ,  Deepu MADDURI

IPC分类号： A61K39/00 ,  A61P35/00 ,  C12Q1/6886

CPC分类号： A61K39/464417 ,  A61K39/4611 ,  A61K39/4631 ,  A61P35/00 ,  C12Q1/6886 ,  A61K2239/38 ,  A61K2239/48 ,  C12Q2600/106 ,  C12Q2600/118

摘要： A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.

公开(公告)号：US20240358754A1

公开(公告)日：2024-10-31

申请号：US18592234

申请日：2024-02-29

申请人： LEGEND BIOTECH USA INC. ,  JANSSEN BIOTECH, INC.

发明人： Nitin PATEL ,  Lida PACAUD ,  Yuhong QIU ,  Nikoletta LENDVAI ,  William DERAEDT ,  Jordan Mark SCHECTER ,  Ana Rute DE ASCENSAO SLAUGHTER ,  Carolina LONARDI

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464417 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2878 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/38 ,  A61K2239/48

摘要： Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.

公开(公告)号：US20230270786A1

公开(公告)日：2023-08-31

申请号：US18175347

申请日：2023-02-27

申请人： JANSSEN BIOTECH, INC. ,  NANJING LEGEND BIOTECH CO., LTD. ,  LEGEND BIOTECH USA INC.

发明人： Xiaohu FAN ,  Jordan SCHECTER ,  Lida PACAUD ,  Michael HIRSCHMANN

IPC分类号： A61K35/17 ,  A61K31/675 ,  A61K31/52 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K35/17 ,  A61K31/675 ,  A61K31/52 ,  A61K45/06 ,  A61P35/00

摘要： Provided herein are methods of treating a subject who has multiple myeloma with a ciltacabtagene autoleucel suspension. Also provided are pharmaceutical products containing ciltacabtagene autoleucel suspensions, instructions for use of the ciltacabtagene autoleucel suspensions, and methods for selling a drug product containing ciltacabtagene autoleucel suspensions.

公开(公告)号：US20230277589A1

公开(公告)日：2023-09-07

申请号：US18052349

申请日：2022-11-03

申请人： JANSSEN BIOTECH, INC. ,  NANJING LEGEND BIOTECH CO., LTD.

发明人： Muhammad AKRAM ,  Kevin DEBRAGANCA ,  Xiaohu FAN ,  Dong GENG ,  Tonia NESHEIWAT ,  Lida PACAUD ,  Jordan SCHECTER ,  Helen VARSOS ,  Enrique ZUDAIRE

IPC分类号： A61K35/17 ,  C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K31/675 ,  A61K31/7076 ,  A61K31/167 ,  A61K31/138 ,  C07K14/705 ,  A61K38/17 ,  C07K14/725

CPC分类号： A61K35/17 ,  A61K31/138 ,  A61K31/167 ,  A61K31/675 ,  A61K31/7076 ,  A61K38/1774 ,  A61K39/3955 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/2866 ,  C07K16/2878 ,  A61K2039/5156

摘要： Provided herein are methods of treating a subject who has multiple myeloma and has received prior treatment and has limited treatment options. Infusions of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0 × 105 to 5.0 × 106 of CAR-T cells per kilogram of the subject’s mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.